Microglial and astrocytic changes in the striatum of methamphetamine abusers

Legal Medicine

Volumn 12, Issue 2, 2010, Pages 57-62

  Kitamura, Osamu ^a   Takeichi, Toshiaki ^a   Wang, Elaine Lu ^a   Tokunaga, Itsuo ^b   Ishigami, Akiko ^b   Kubo, Shin ichi ^c  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Astrocytes; Drug addiction; Methamphetamine; Microglia; Neuroroxicity; Striatum

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE TRANSPORTER 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHAMPHETAMINE; PROTEIN S100B;

ADULT; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABUSE; DRUG INTOXICATION; FEMALE; FORENSIC PATHOLOGY; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NEUROPATHOLOGY; NEUROTOXICITY;

ADULT; AMPHETAMINE-RELATED DISORDERS; ASTROCYTES; BASAL GANGLIA; FEMALE; FORENSIC TOXICOLOGY; HUMANS; IMMUNOCHEMISTRY; MALE; METHAMPHETAMINE; MICROGLIA; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 76849108568     PISSN: 13446223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.legalmed.2009.11.001     Document Type: Article

References (46)

1. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker Jr. W., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268 (1994) 1571-1580
2. O'Callaghan J.P., and Miller D.B. Neurotoxicity profiles of substituted amphetamine in the C57BL/6J mouse. J Pharmacol Exp Ther 270 (1994) 741-751
3. Frey K., Kilbourn M., and Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334 (1997) 273-279
4. Fukumura M., Cappon G.D., Pu C., Broening H.W., and Vorhees C.V. A single dose of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res 806 (1998) 1-7
5. Cappon G.D., Pu C., and Vorhees C.V. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single dose treatment. Brain Res 863 (2000) 106-111
6. Johnson-Davis K.L., Fleckenstein A.E., and Wilkins D.G. The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482 (2003) 151-154
7. Segal D.S., Kuczenski R., O'Neil M.L., Melega W.P., and Cho A.K. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28 (2003) 1730-1740
8. Nakajima A., Yamada K., Nagai T., Uchiyama T., Miyamoto Y., Mamiya T., et al. Role of tumor-necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 24 (2004) 2212-2225
9. De Vito M.J., and Wagner G.C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28 (1989) 1145-1150
10. Cadet J.L., and Brannock C. Free radicals and the pathology of brain dopamine systems. Neurochem Int 32 (1998) 117-131
11. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19 (1999) 1484-1491
12. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., and Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography. J Neurosci 18 (1998) 8417-8422
13. Sekine Y., Iyo M., Ouchi Y., Yoshikawa E., Matsunaga T., Tsukada H., et al. Methamphetamine-related symptoms and reduced brain dopamine transporters studies with PET. Am J Psychiatry 158 (2003) 1206-1214
14. Wilson J.M., Kalasinski K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.T., et al. Striatal dopamine nerve terminals markers in human, chronic methamphetamine users. Nature Med 2 (1996) 699-703
15. Kitamura O., Tokunaga I., Gotohda T., and Kubo S. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121 (2007) 163-168
16. Hanisch H.K. Microglia as a source and target of cytokines. Glia 40 (2002) 140-155
17. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40 (2002) 133-139
18. Kim S.U., and de Vellis J. Microglia in health and disease. J Neurosci Res 81 (2005) 302-311
19. Streit W.J. Microglial cells. In: Ketterman H., and Ransom B.R. (Eds). Neuroglia. 2nd ed. (2005), Oxford University Press, New York 60-71
20. Escubedo E., Guitart L., Sureda F.X., Jiménez A., Pubill D., Pallàs M., et al. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 814 (1998) 120-126
21. Asanuma M., Tsuji T., Miyazaki I., Miyoshi K., and Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketaprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 352 (2003) 13-16
22. LaVoie M.J., Card J.P., and Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187 (2004) 47-57
23. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., and Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367 (2004) 349-354
24. Thomas D.M., and Kuhn D.M. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92 (2005) 790-797
25. Benarroch E.E. Neuron-astrocyte interaction: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 80 (2005) 1326-1338
26. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200 (2002) 629-638
27. Nedergaard M., Ransom B., and Goldman S.A. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci 26 (2003) 523-530
28. Ridet J.L., Malhorta S.K., Privat A., and Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 23 (1997) 570-577
29. O'Callaghan J.P. Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. Ann NY Acad Sci 679 (1993) 195-210
30. Pubill D., Canudas A.M., Pallás M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Arch Pharmacol 367 (2003) 490-499
31. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., et al. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
32. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28 (2008) 5756-5761
33. Mirecki A., Fitzmaurice P., Ang L., Kalasinski K.S., Peretti F.J., Aiken S.S., et al. Brain antioxidant systems in human methamphetamine users. J Neurochem 89 (2004) 1398-1408
34. Payne J., Maher F., Simpson I., Mattice L., and Davies P. Glucose transporter GLUT5 expression in microglial cells. Glia 21 (1997) 327-331
35. Horikoshi Y., Sasaki A., Taguchi N., Maeda M., Tsukagoshi H., Sato K., et al. Human GLUT5 immunolabeling is useful for evaluating microglial status in neuropathological study using paraffin sections. Acta Neuopathol 105 (2003) 157-162
36. Sasaki A., Horikoshi Y., Yokoo H., Nakazato Y., and Yamaguchi H. Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett 338 (2003) 17-20
37. Gräber M.B., Bise K., and Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol Appl Neurobiol 20 (1994) 406-408
38. Rothermundt M., Peters M., Prehn J.H.M., and Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 60 (2003) 614-632
39. Li D.R., Zhu B.L., Ishikawa T., Zhao D., Michiue T., and Maeda H. Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy. Legal Med 8 (2006) 78-85
40. Steiner J., Bernstein H.-G., Bielau H., Berndt A., Brisch R., Mawrin C., et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BCM Neurosci 8 (2007) 2
41. Ishigami A., Tokunaga I., Gotohda T., and Kubo S. Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers. Legal Med 5 (2003) 42-48
42. Stadlin A., Lau J.W.S., and Szeto Y.K. A selective regional response of cultured astrocytes to methamphetamine. Ann NY Acad Sci 844 (1998) 108-121
43. Oehmichen M., Meißner C., Reiter A., and Birkholz M. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathol 91 (1996) 642-646
44. Büttner A., and Weis S. Neuropathological alterations in drug abusers - the involvement of neurons, glial and vascular systems. Forensic Sci Med Pathol 2 (2006) 115-126
45. In S.W., Son E.W., Rhee D.K., and Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 68 (2005) 2133-2145
46. Langford D., Adame A., Grigorian A., Grant I., MacCutchan J., Ellis R.J., et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 34 (2003) 467-474